In vitro and in vivo anti-inflammatory effects of IMMLG5521, a coumarin derivative

- The anti-inflammatory effects of IMMLG5521, a coumarin derivative, were studied in vitro and in vivo.
- Compound IMMLG5521 inhibited the release of β-glucuronidase from PAF-stimulated polymorphonuclear leukocytes.
- Compound IMMLG5521 inhibited the release of inflammatory factors from LPS-stimulated RAW264.7 cells.
- Compound IMMLG5521 inhibited xylene-induced ear swelling in mice.
- Compound IMMLG5521 inhibited cotton pellet-induced granuloma formation in mice.

Several coumarin derivatives have been reported to present multiple biological activities. In this study, in vitro the compound IMMLG5521 (0.1, 1, 10 μM) can inhibit the release of β-glucuronidase from PAF-stimulated polymorphonuclear leukocytes, the compound IMMLG5521 (0.1, 1, 10 μM) can inhibit NO production and decrease TNF-α and IL-β release from LPS-stimulated RAW264.7 cells. In vivo, we evaluated the effect of IMMLG5521 on acute and chronic inflammation models. Our data showed that IMMLG5521 (6 mg/kg, 12 mg/kg) could inhibit xylene-induced ear swelling and cotton pellet-induced granuloma formation in mice. Taken together, the compound IMMLG5521 inhibited the release of inflammatory factors and mediators in vitro, decreased inflammation response in mice. The compound IMMLG5521 can inhibit inflammation in vitro and in vivo.